Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Primary Care
Is there any concern with starting romosozumab in a patient who is taking raloxifene for a history of breast cancer?
Related Questions
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
Would you consider PTH analogue in a patient with mildly elevated PTH?
How would you manage a middle-aged patient with Paget's disease who received one dose of zolendronic acid 2 years ago, currently suppressed CTX, normal bone-specific Alkaline phos, and a recent hairline fracture in the thoracic spine?
Would you have concerns about combining romosuzumab and IVIG in a patient with dermatomyositis and osteoporosis?
Would you order a repeat DEXA scan 1 year later for a kidney transplant patient who had an initial DEXA scan within the first 6 months post-transplant showing osteopenia but no history of fractures, and who has been stable on glucocorticoid-free immunosuppressive therapy?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
How do you use P1NP in your clinical practice to guide management of osteoporosis?
Would you stop denosumab in a patient with chronic kidney disease if they develop asymptomatic hypocalcemia after the injection?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
What is your approach to management of patients with recurrent nephrolithiasis and osteoporosis who are receiving teriparatide?
